Zobrazeno 1 - 10
of 51
pro vyhledávání: ''
Autor:
Kaiyan Chen, Xiaoqing Yu, Zhiyu Huang, Yun Fan, Guoping Cheng, Yanjun Xu, Fanrong Zhang, Guanxia Zhu
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 142
The efficacy of immunotherapy in epidermal growth factor receptor (EGFR)-activating non-small cell lung cancer (NSCLC) is limited. However, a series of patients with uncommon EGFR alterations was reported to derive clinical benefit from PD-1 blockade
Autor:
Hui Sun, Chao Zhao, Wei Li, Xiaoxia Chen, Caicun Zhou, Chunyan Wang, Shuo Yang, Fengying Wu, Yayi He, Xuefei Li, Yiwei Liu, Shiqi Mao, Yingying Pan, Shengxiang Ren, Xiaofei Yu, Chunxia Su, Qian Liu, Yan Wang, Anwen Xiong, Guanghui Gao, Bin Chen
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 139
Advanced non-small cell lung cancer (NSCLC) patients harboring non-resistant uncommon epidermal growth factor receptor (EGFR) mutations have stepped into the era of targeted therapy. This study aimed to investigate the incidence of acquired T790M mut
Autor:
Yoichi Nakanishi, Renpeng Liu, Hiroshi Wataya, Keiichi Ota, Yasuto Yoneshima, Yuki Ikematsu, Yuriko Takahata, Kentaro Tanaka, Hiroyuki Inoue, Kentaro Hata, Eiji Iwama, Isamu Okamoto, Toyoshi Yanagihara, Shohei Takata
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 138
Objectives Pleural effusion (PE) occasionally develops in cancer patients during treatment with antibodies to programmed cell death–1 (PD-1) or to its ligand PD-L1 (hereafter, αPD-1 therapy). Such effusion often contains infiltrated mononuclear ce
Autor:
Aya Miyagawa-Hayashino, Masayoshi Inoue, Yuta Sonobe, Takahiro Yamada, Tadaaki Yamada, Satoru Okada, Masahiro Iwasaku, Koichi Takayama, Yusuke Chihara, Eiichi Konishi, Tatsuya Imabayashi, Takayuki Shimamoto, Yoshiko Kaneko, Akihiro Yoshimura, Junji Uchino
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 137
Objective Small cell lung cancer (SCLC), which accounts for approximately 15% of all lung cancer cases, has high initial sensitivity to chemotherapy. However, clinical outcomes have not improved in the past two decades. Therefore, novel biomarkers ar
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 140
Objectives Tyrosine kinase inhibitor (TKI) has been the standard of care for advanced non-small cell lung cancers (NSCLC) harboring epidermal growth factor receptor (EGFR) mutation, but these tumors invariably develop drug resistance. As progression
Autor:
Keunchil Park, Martin Schuler, Yi-Long Wu, Vera Hirsh, Ki Hyeong Lee, Caicun Zhou, Shun Lu, Angela Märten, Stuart H. Ellis, James Chih-Hsin Yang, W. Tang, Luis Paz-Ares, Carl Samuelsen, E. Ehrnrooth, Lecia V. Sequist, Jifeng Feng
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 133
Objectives In patients with advanced epidermal growth factor receptor mutation-positive (EGFRm+) non-small cell lung cancer (NSCLC), first-line afatinib significantly improved progression-free survival (PFS) and objective response vs. platinum-double
Autor:
Sukhmani K. Padda, Joseph B. Shrager, Summer S. Han, Joel W. Neal, Christian A. Kunder, Jacqueline V. Aredo, Heather A. Wakelee
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 133
Concurrent genetic mutations are prevalent in KRAS-mutant non-small cell lung cancer (NSCLC) and may differentially influence patient outcomes. We sought to characterize the effects of KRAS mutation subtypes and concurrent pathogenic mutations on ove
Autor:
Kenneth J. O'Byrne, Jaafar Bennouna, Vera Hirsh, Kazuhiko Nakagawa, Eng Huat Tan, Yi-Long Wu, Tony Mok, Shun Lu, Li Zhang, James Chih-Hsin Yang, Martin Schuler, Toyoaki Hida, Hiroshi Tanaka, Terufumi Kato, Keunchil Park, Denis Moro Sibilot, Michael Boyer, Nobuyuki Yamamoto, Angela Märten, Caicun Zhou, W. Tang, Luis Paz-Ares
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 132
Objectives With the availability of several epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), sequential therapy could potentially render EGFR mutation-positive non-small cell lung cancer a chronic disease in some patients. I
Autor:
Christian Asel, David Lang, Elmar Brehm, Klaus Langer, Bernhard Kaiser, Benedikt Hergan, Andreas Horner, Kaveh Akbari, Bernd Lamprecht, Mario Scala
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 134
To evaluate serum tumor markers (STM) as biomarkers for treatment monitoring and prognosis in advanced non-small cell lung cancer (NSCLC) treated with single-agent PD-1/PD-L1-directed immune checkpoint inhibitor (ICI) therapy.Carcinoembryonic antigen
Autor:
Yunzhong Zhu, Ying Cheng, Xiaoqing Liu, Cheng Huang, E. Li, Houjie Liang, Yi-Long Wu, Shukui Qin, Gang Wu, Guo-Liang Jiang, Zhaoyang Zhong, Baohui Han, Caicun Zhou, Shun Lu, Lei Chen, Hongming Pan
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 130
Objectives Sequential combination of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) and chemotherapy has shown greater benefits than either treatment alone in non-small-cell lung cancer (NSCLC). In this follow-up of the ENS